
What happened
Pfizer CSO Chris Boshoff said the company aims to cut first-in-human time from roughly four years to two, and then halve Phase 1 to approval, building AI into its R&D decision cycles.
Why it matters
If achieved, halving these timelines could bring medicines to patients years sooner and reshape how the company prioritizes its pipeline, though the targets remain goals rather than results.
WHO IT HITSPfizer's R&D scientists and safety staff are the immediate users, with over 15,000 R&D colleagues already using AI tools and safety scientists handling more than 100,000 submissions a month. Patients waiting for new medicines could feel the effect if the timeline goals are met.
Summaries like this, every morning.
Pfizer's push is framed around what it calls decision cycles, not generic productivity. Drug development, as Boshoff describes it, is a race measured in decisions: whether a target, molecule or dose is right, which populations to study, and whether to keep going or stop. Evidence for those calls has historically been assembled by disconnected digital systems, debated in committees and handed between teams over months. The company's stated goal is to turn days or weeks of evidence assembly into answers it can act on in hours.
The foundation for that is data. Pfizer says its scientists have generated petabytes of proprietary data over decades, much of it archived across different systems after serving its original purpose. The company is now curating and standardizing that data, connecting it across sources and ensuring every result can be traced back to its origin, so that past evidence can inform the next decision. Boshoff describes the vision as an R&D enterprise that learns at the rate of evidence and reasons from a shared platform.
Pfizer is also staffing up for the effort. Arpita Saha recently joined as its first Chief R&D AI Officer after AI leadership roles at Tempus and Google, and Eric Schadt is working with the company as its R&D AI Scholar. Alongside internal work, Pfizer has a license agreement with Chai Discovery for the design of antibodies and other biologics, and a partnership with Cartography to identify potential novel targets for biologics.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
At Open Source Summit Europe 2026 in Prague, a Texas Instruments-moderated panel said embedded engineers are b…

A Seeking Alpha analyst upgraded Broadcom (AVGO) to Strong Buy, arguing it should lead investors out of the cu…

Dell shares are up 165.55% year to date but 26.68% lower over the past month, at $330.75 versus a 52-week high…

Intel is promoting laptops with its Core Ultra chips as AI PCs for the holidays, spotlighting on-device featur…

On the Nov. 19 earnings call, CEO John Furner said U.S

On a Q3 2027 earnings call, CEO John Furner said Walmart is preparing its omnichannel experience for internal…
